United States News All stories

MarketAxess Holdings (NASDAQ:MKTX) reported third-quarter 2026 revenue of $210.4 million, up 1% year over year, supported by growth in information and other services revenue.

The Gorman-Rupp Company (NYSE:GRC) reported record third-quarter 2026 net sales of $193.3 million, up 11.8% year over year, as demand and pricing improved across its markets.

First Citizens BancShares (NASDAQ:FCNCA) reported third-quarter 2026 net income of $606 million, down 9.8% sequentially, while earnings per common share declined to $51.23.

First Citizens BancShares (NASDAQ:FCNCA) declared a quarterly common stock dividend of $2.25 per share, covering both Class A and Class B common shares.

Zymeworks (NASDAQ:ZYME) entered an exclusive global license and collaboration agreement with Roche for its experimental cancer treatment ZW209, with a $55 million upfront payment.

IDEAYA Biosciences (NASDAQ:IDYA) reported updated Phase 1 results for IDE849, showing a 60.8% confirmed objective response rate in second-line small cell lung cancer patients.

Flagstar Bank (NYSE:FLG) reported third-quarter 2026 net income attributable to common stockholders of $3 million, or $0.01 per diluted share, down from $26 million in the previous quarter.

Eni (NYSE:E) reported third-quarter 2026 adjusted net profit of €2.8 billion, more than doubling from a year earlier as higher production and a favorable commodity market supported earnings.

Phathom Pharmaceuticals (NASDAQ:PHAT) announced that BDR Pharmaceuticals International has filed a lawsuit against the U.S. Food and Drug Administration challenging regulatory exclusivity protections for VOQUEZNA tablets.

Veracyte (NASDAQ:VCYT) reported an analysis of Phase III STAMPEDE trial data suggesting its Decipher Prostate test may help identify patients who benefit from adding abiraterone to treatment.

Oil prices rose more than 1% on Friday as Houthi attacks in Saudi Arabia heightened concerns about further disruptions to energy supplies from the Middle East.

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported initial Phase 1b results showing that brezosiran reduced cerebrospinal fluid mutant huntingtin protein by an average of 60%–64% after three months in the highest dose group evaluated.

Sensata Technologies (NYSE:ST) announced that its Board of Directors approved a fourth-quarter 2026 cash dividend of $0.12 per share.

Evaxion (NASDAQ:EVAX) reported sustained three-year responses in its Phase 2 EVX-01 melanoma trial, with 89% of vaccine targets generating specific T-cell responses.

ORIC Pharmaceuticals (NASDAQ:ORIC) reported Phase 1b enozertinib results showing an 84% confirmed tumor response rate in previously untreated lung cancer patients.

NVR (NYSE:NVR) reported third-quarter 2026 net income of $248.6 million, down 27%, while consolidated revenue declined to $2.40 billion.

Procter & Gamble (NYSE:PG) reported fiscal first-quarter 2027 net sales of $23.3 billion, up 4%, supported by higher consumer product volumes.

TriCo Bancshares (NASDAQ:TCBK) reported third-quarter 2026 net income of $38 million, up 11.1% sequentially, while diluted earnings reached $1.18 per share.

Curbline Properties (NYSE:CURB) reported third-quarter 2026 Operating FFO of $37.4 million, up 26.7%, while net income declined to $7.4 million.

Amalgamated Financial (NASDAQ:AMAL) reported record third-quarter 2026 net income of $36.4 million, or $1.20 per diluted share.

FirstCash Holdings (NASDAQ:FCFS) reported third-quarter 2026 revenue of $1.101 billion, up 18% year over year, supported by growth across pawn operations.

Carpenter Technology (NYSE:CRS) reported fiscal first-quarter 2027 operating income of $196.4 million, up 28%, while sales increased 9% to $798.2 million.

Badger Meter (NYSE:BMI) reported third-quarter 2026 sales of $235.9 million, compared with $235.7 million a year earlier, while operating earnings increased 4%.

TTM Technologies (NASDAQ:TTMI) reported third-quarter 2026 sales of $1.2 billion, up 60% year over year, supported by its expanding technology operations.